No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 1946-1957

  Reijnders, Christianne M A ^a   Waaijer, Cathelijn J F ^a   Hamilton, Andrew ^b   Buddingh, Emilie P ^a   Dijkstra, Sander P D ^a   Ham, John ^c   Bakker, Egbert ^a   Szuhai, Karoly ^a   Karperien, Marcel ^d   Hogendoorn, Pancras C W ^a   Stringer, Sally E ^b   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ADIPOGENESIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; EXT GENE; FLOW CYTOMETRY; GENETIC PARAMETERS; HAPLOINSUFFICIENCY; HETEROZYGOSITY LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; MUTATIONAL ANALYSIS; OSTEOCHONDROMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 77957356448     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.100296     Document Type: Article

References (46)

1. Khurana J, Abdul-Karim F, Boveacute;e JVMG: Osteochondroma. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Edited by CDM Fletcher, KK Unni, and F Mertens. Lyon, France, IARC Press, 2002, pp. 234-236
2. Boveacute;e JVMG Hogendoorn PCW: Congenital and inherited syndromes associated with bone and soft tissue tumours: Multiple osteochondromas. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Edited by CDM Fletcher, KK Unni, and F Mertens. Lyon, France, IARC Press, 2002, pp. 360-362
3. Legeai-Mallet L, Munnich A, Maroteaux P, Le Merrer M: Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clin Genet 1997, 52:12-16
4. Bovée JVMG: Multiple osteochondromas. Orphanet J Rare Dis 2008, 3:3
5. Knudson AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823
6. Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB, Clines GA, Ludecke HJ, Lovett M, Van Winkle WB, Hecht JT: Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes. Cell Motil Cytoskeleton 2001, 48:149-162
7. Bovée JVMG, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AHM, Bakker E, Van Hul W, Cornelisse CJ, Hogendoorn PCW: EXTmutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. Am J Hum Genet 1999, 65:689-698
8. Hameetman L, Szuhai K, Yavas A, Knijnenburg J, van Duin M, Van Dekken H, Taminiau AHM, Cleton-Jansen AM, Boveacute;e JVMG, Hogendoorn PCW: The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. J Natl Cancer Inst 2007, 99:396-406
9. Hallor KH, Staaf J, Boveacute;e JVMG, Hogendoorn PCW, Cleton-Jansen AM, Knuutila S, Savola S, Niini T, Brosjo O, Bauer HCF, Vult von Steyern F, Jonsson K, Skorpil M, Mandahl N, Mertens F: Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors. Clin Cancer Res 2009, 15:2685-2694
10. Hecht JT, Hogue D, Strong LC, Hansen MF, Blanton SH, Wagner M: Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome 11 and loss of heterozygosity for EXT-linked markers on chromosomes 11 and 8. Am J Hum Genet 1995, 56:1125-1131
11. Raskind WH, Conrad EU, Chansky H, Matsushita M: Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet 1995, 56:1132-1139
12. Bernard MA, Hogue DA, Cole WG, Sanford T, Snuggs MB, Montufar- Solis D, Duke PJ, Carson DD, Scott A, Van Winkle WB, Hecht JT: Cytoskeletal abnormalities in chondrocytes with EXT1 and EXT2 mutations. J Bone Miner Res 2000, 15:442-450
13. Hall CR, Cole WG, Haynes R, Hecht JT: Reevaluation of a genetic model for the development of exostosis in hereditary multiple exostosis. Am J Med Genet 2002, 112:1-5
14. Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza R, Mallet JF, Delezoide AL, Munnich A, Bonaventure J, Zylberberg L: EXT 1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses. J Bone Miner Res 2000, 15:1489-1500
15. Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K: The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 1998, 273:26265-26268
16. McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, Tufaro F: The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 1998, 19:158-161
17. McCormick C, Duncan G, Goutsos KT, Tufaro F: The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA 2000, 97:668-673
18. Simmons AD, Musy MM, Lopes CS, Hwang L-Y, Yang Y-P, Lovett M: A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses. Hum Mol Genet 1999, 8:2155-2164
19. Bellaiche Y, The I, Perrimon N: Tout-velu is a drosophila homologue of the putative tumour suppressor EXT1 and is needed for Hh diffusion. Nature 1998, 394:85-88
20. Han C, Belenkaya TY, Khodoun M, Tauchi M, Lin X, Lin X: Distinct and collaborative roles of Drosophila EXT family proteins in morphogen signalling and gradient formation. Development 2004, 131:1563-1575
21. Takei Y, Ozawa Y, Sato M, Watanabe A, Tabata T: Three Drosophila EXT genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans. Development 2004, 131:73-82
22. Toyoda H, Kinoshita-Toyoda A, Selleck SB: Structural analysis of glycosaminoglycans in drosophila and caenorhabditis elegans and demonstration that tout-velu, a drosophila gene related to EXT tumor suppressors, affects heparan sulfate in vivo. J Biol Chem 2000, 275:2269-2275
23. Hameetman L, David G, Yavas A, White SJ, Taminiau AHM, Cleton- Jansen AM, Hogendoorn PCW, Boveacute;e JVMG: Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas. J Pathol 2007, 211:399-409
24. Benoist-Lasselin C, de Margerie E, Gibbs L, Cormier S, Silve C, Nicolas G, Lemerrer M, Mallet JF, Munnich A, Bonaventure J, Zylberberg L, Legeai-Mallet L: Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. Bone 2006, 39:17-26
25. Hameetman L, Rozeman LB, Lombaerts M, Oosting J, Taminiau AHM, Cleton-Jansen AM, Boveacute;e JVMG, Hogendoorn PCW: Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog (IHH) signalling. J Pathol 2006, 209:501-511
26. Boveacute;e JVMG, Van den Broek LJCM, Cleton-Jansen AM, Hogendoorn PCW: Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000, 80:1925-1933
27. Hameetman L, Kok P, Eilers PHC, Cleton-Jansen AM, Hogendoorn PCW, Boveacute;e JVMG: The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005, 446:430-437
28. Vink GR, White SJ, Gabelic S, Hogendoorn PCW, Breuning MH, Bakker E: Mutation screening of EXT1 and EXT2 by direct sequence analysis and MLPA in patients with multiple osteochondromas: splice site mutations and exonic deletions account for more than half of the mutations. Eur J Hum Genet 2004, 13:470-474
29. White SJ, Vink GR, Kriek M, Wuyts W, Schouten J, Bakker B, Breuning MH, den Dunnen JT: Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat 2004, 24:86-92
30. Schrage YM, Hameetman L, Szuhai K, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW, Boveacute;e JVMG: Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. Am J Pathol 2009, 174:979-988
31. Chen E, Stringer SE, Rusch MA, Selleck SB, Ekker SC: A unique role for 6-O sulfation modification in zebrafish vascular development. Dev Biol 2005, 284:364-376
32. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE: VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006, 281:1731-1740
33. Wasteson A: A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. J Chromatogr 1971, 59:87-97
34. David G, Bai XM, Van der Schueren B, Marynen P, Cassiman JJ, Van den Berghe H: Spatial and temporal changes in the expression of fibroglycan (syndecan-2) during mouse embryonic development. Development 1993, 119:841-854
35. Boveacute;e JVMG, Cleton-Jansen AM, Kuipers-Dijkshoorn N, Van den Broek LJCM, Taminiau AHM, Cornelisse CJ, Hogendoorn PCW: Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chrom Cancer 1999, 26:237-246
36. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z: Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 2005, 132:5055-5068
37. Knox S, Merry C, Stringer S, Melrose J, Whitelock J: Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem 2002, 277:14657-14665
38. Yamada S, Busse M, Ueno M, Kelly OG, Skarnes WC, Sugahara K, Kusche-Gullberg M: Embryonic fibroblasts with a gene trap mutation in EXT1 produce short heparan sulphate chains. J Biol Chem 2004, 279:32134-32141
39. Busse M, Feta A, Presto J, Wilen M, Gronning M, Kjellen L, Kusche- Gullberg M: Contribution of EXT1. EXT2, and EXTL3 to heparan sulfate chain elongation J Biol Chem 2007, 282:32802-32810
40. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, Matzuk MM: Disruption of gastrulation and heparan sulfate biosynthesis in EXT1- deficient mice. Dev Biol 2000, 224:299-311
41. Shi X, Zaia J: Organ-specific heparan sulfate structural phenotypes. J Biol Chem 2009, 284:11806-11814
42. Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J, Benassi MS, Franchi A, Patino A, Ward LS, Boveacute;e J, Igudosa JC, Im W, Steller M: Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells. Hum Mol Genet 2004, 13:2753-2765
43. Tsuchiya T, Osanai T, Ogose A, Tamura G, Chano T, Kaneko Y, Ishikawa A, Orui H, Wada T, Ikeda T, Namba M, Takigawa M, Kawashima H, Hotta T, Tsuchiya A, Ogino T, Motoyama T: Methylation status of EXT1 and EXT2 promoters and two mutations of EXT2 in chondrosarcoma. Cancer Genet Cytogenet 2005, 158:148-155
44. Hilton MJ, Gutierrez L, Martinez DA, Wells DE: EXT1 regulates chondrocyte proliferation and differentiation during endochondral bone development. Bone 2005, 36:379-386
45. Jones KB, Piombo V, Searby C, Kurriger G, Yang B, Grabellus F, Roughley PJ, Morcuende JA, Buckwalter JA, Capecchi MR, Vortkamp A, Sheffield VC: A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA 2010, 107:2054-2059
46. Clement A, Wiweger M, von der HS, Rusch MA, Selleck SB, Chien CB, Roehl HH: Regulation of zebrafish skeletogenesis by ext2/dackel and papst1/pinscher. PLoS Genet 2008, 4:e1000136